SEC Form 4 · accession 0001493152-26-037509
TAKEDA PHARMACEUTICAL CO LTD · TAK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lauren Rusckowski Duprey
Officer — Chief Transformation Officer
Period of report
Aug 10, 2026
Accepted (ET)
Aug 12, 2026 · 9:51 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001395064
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| American Depositary SharesF2 | Aug 10, 2026 | S | 47,586 | $17.10 | D | 226,057 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person.
- F2The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.